Chimeric Therapeutics Limited (ASX:CHM)
Australia flag Australia · Delayed Price · Currency is AUD
0.0020
0.00 (0.00%)
Mar 4, 2026, 3:56 PM AEST

Chimeric Therapeutics Cash Flow Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Net Income
-18.79-10.43-12.53-25.92-15.9-15.11
Depreciation & Amortization
1.031.031.080.970.950.85
Loss (Gain) From Sale of Assets
000.0100-
Asset Writedown & Restructuring Costs
-0.09-0.091.26---
Stock-Based Compensation
1.091.090.893.323.172.1
Other Operating Activities
6.54-0.60.151.470.841
Change in Accounts Receivable
-0.01-0.013.56-0.99-2.63-0.02
Change in Accounts Payable
1.941.94-1.984.740.322.59
Change in Other Net Operating Assets
-0.2-0.20.010.10.1-0.23
Operating Cash Flow
-8.49-7.28-7.54-16.31-13.15-8.83
Capital Expenditures
-----0.01-0.02
Sale (Purchase) of Intangibles
----0.11-0.53-5.29
Investment in Securities
-----0.04-
Investing Cash Flow
-0.24---0.11-0.58-5.31
Short-Term Debt Issued
-----0.86
Total Debt Issued
-1.56----0.86
Short-Term Debt Repaid
------0.89
Long-Term Debt Repaid
---2.28-2.23-4.05-
Total Debt Repaid
-2.54--2.28-2.23-4.05-0.89
Net Debt Issued (Repaid)
-4.1--2.28-2.23-4.05-0.03
Issuance of Common Stock
98.211.742.5814.939.3
Other Financing Activities
1.391.84-1.21-0.1-1.31-2.72
Financing Cash Flow
6.2810.058.260.259.5436.54
Foreign Exchange Rate Adjustments
-0.11-0.07-0.030.150.160.01
Net Cash Flow
-2.562.70.69-16.02-4.0322.41
Free Cash Flow
-8.49-7.28-7.54-16.31-13.17-8.85
Free Cash Flow Margin
-87.11%-57.36%-101.07%-361.89%-503.04%-
Free Cash Flow Per Share
-0.00-0.01-0.01-0.04-0.04-0.05
Cash Interest Paid
--0.010.01-0.01
Cash Income Tax Paid
--4.17-7.34-3.5--
Levered Free Cash Flow
-4.94-2.15-3.7-10.45-6.8-4.57
Unlevered Free Cash Flow
-4.75-2.02-3.49-9.97-6.4-4.57
Change in Working Capital
1.731.731.63.85-2.212.33
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.